Swiss Parenterals Limited — Meropenem Exporter Profile
Indian Pharmaceutical Exporter · #10 for Meropenem · $2.0M export value · DGFT Verified
Swiss Parenterals Limited is the #10 Indian exporter of Meropenem with $2.0M in export value and 46 verified shipments. Swiss Parenterals Limited holds a 0.9% market share in Meropenem exports across 14 countries. The company exports 18 pharmaceutical products worth $15.9M across 9 therapeutic categories.
Swiss Parenterals Limited — Meropenem Export Profile: Buyers & Destinations
Where Does Swiss Parenterals Limited Export Meropenem?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RWANDA | $258.9K | 9 | 21.3% |
| PHILIPPINES | $200.0K | 4 | 16.5% |
| IRAQ | $164.0K | 8 | 13.5% |
| VENEZUELA | $150.0K | 3 | 12.4% |
| NIGERIA | $111.7K | 3 | 9.2% |
| NICARAGUA | $98.9K | 7 | 8.2% |
| MOLDOVA | $65.6K | 4 | 5.4% |
| SRI LANKA | $50.0K | 1 | 4.1% |
| ZIMBABWE | $47.4K | 1 | 3.9% |
| LEBANON | $19.9K | 1 | 1.6% |
Swiss Parenterals Limited exports Meropenem to 15 countries. The largest destination is RWANDA accounting for 21.3% of Swiss Parenterals Limited's Meropenem shipments, followed by PHILIPPINES (16.5%) and IRAQ (13.5%). These destinations reflect Swiss Parenterals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Meropenem from Swiss Parenterals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | NICARAGUA | $637.9K | 27 |
| TO THE ORDER OF | MOLDOVA | $225.4K | 8 |
| TO THE ORDER | THAILAND | $115.6K | 5 |
| TO THE ORDER OF ASIA UNITED BANK CO | PHILIPPINES | $100.0K | 2 |
| TO THE ORDER OF ... | NIGERIA | $36.0K | 1 |
| TO THE ORDER OF | NIGERIA | $25.7K | 1 |
| TO THE ORDER OF.. | RWANDA | $15.3K | 1 |
Swiss Parenterals Limited supplies Meropenem to 7 buyers globally. The largest buyer is TO THE ORDER OF (NICARAGUA), followed by TO THE ORDER OF (MOLDOVA) and TO THE ORDER (THAILAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Meropenem Export Value and How Much Does Swiss Parenterals Limited Contribute?
India exported $80.5M worth of Meropenem through 3,658 shipments from 401 suppliers to 134 countries, serving 966 buyers globally. Swiss Parenterals Limited contributes $2.0M to this total, accounting for 0.9% of India's Meropenem exports. Swiss Parenterals Limited ships Meropenem to 15 countries through 7 buyers.
What Is the Average Shipment Value for Swiss Parenterals Limited's Meropenem Exports?
Swiss Parenterals Limited's average Meropenem shipment value is $43.1K per consignment, based on 46 shipments totaling $2.0M. The largest destination is RWANDA (21.3% of Swiss Parenterals Limited's Meropenem exports).
How Does Swiss Parenterals Limited Compare to Other Indian Meropenem Exporters?
Swiss Parenterals Limited ranks #10 among 401 Indian Meropenem exporters with a 0.9% market share. The top 3 exporters are VENUS REMEDIES LIMITED ($40.0M), EUGIA PHARMA SPECIALITIES LIMITED ($17.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($10.3M). Swiss Parenterals Limited processed 46 shipments to 14 destination countries.
What Meropenem Formulations Does Swiss Parenterals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTION1GM (SWISSENEM 1000)NOS | $110.0K | 4 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-MEROPENEM FOR INJECTION 1GMNOS | $96.2K | 3 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTION500MG (SWISSENEM 500)NOS | $54.0K | 4 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTION500MG USP DETAIL AS PER DOCUMENT | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTIONUSP 1 GM MEROMENEG 1 GM | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTION500MG (MEROPEN) | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJECTION1GM (MEROPEN) | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROPENEM FOR INJ USP 1GM (DETAIL AS PER INVOICE) (14520 PACKS)NOS | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-MEROPENEM FOR INJECTION 1GM MESPEN 1 G | $50.0K | 1 |
| PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE-MEROPENEM FOR INJECTION 1GM MESPEN 1 GM | $50.0K | 1 |
Swiss Parenterals Limited exports 37 distinct Meropenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL GOODS/HARMLESS MEDICINESFOR HUMAN USE - MEROP with 4 shipments worth $110.0K.
How Does Swiss Parenterals Limited Compare to Nearest Meropenem Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $10.3M | 206 | 16 | $50.0K |
| 5 | BROOKS STERISCIENCE LIMITED | $2.3M | 45 | 9 | $50.0K |
| 10 | SWISS PARENTERALS LIMITED ★ | $2.0M | 46 | 14 | $43.1K |
| 6 | VENUS REMEDIES LTD | $1.6M | 33 | 10 | $50.0K |
| 9 | GLAND PHARMA LIMITED | $1.6M | 33 | 2 | $50.0K |
Swiss Parenterals Limited ranks #10 among 401 Indian Meropenem exporters. Average shipment value of $43.1K compared to the market average of $200.8K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and BROOKS STERISCIENCE LIMITED.
Which Indian Ports Ship Meropenem Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 504 | 13.8% |
| DELHI AIR | 494 | 13.5% |
| SAHAR AIR | 256 | 7.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 246 | 6.7% |
| NHAVA SHEVA SEA (INNSA1) | 233 | 6.4% |
| CMA CGM LOGISTICS PARK ICD (INCPL6) | 198 | 5.4% |
| Delhi Air | 103 | 2.8% |
| DHANNAD ICD (INDHA6) | 94 | 2.6% |
What Other Advanced Antibiotics Products Does Swiss Parenterals Limited Export?
Swiss Parenterals Limited also exports these advanced antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Swiss Parenterals Limited's Meropenem Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like Swiss Parenterals. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended delivery times. Such maritime challenges can significantly impact the timely distribution of pharmaceuticals, especially to Middle Eastern markets. (pharmaceuticalcommerce.com)
Conversely, escalating US-China trade tensions have prompted the United States to diversify its import sources, potentially benefiting Indian exporters. However, recent US tariff policies, including a 25% tariff on Indian imports due to geopolitical alignments, pose a substantial challenge, potentially affecting nearly 55% of India's exports to the US. (apnews.com)
In the European Union, stringent regulatory frameworks like the Falsified Medicines Directive necessitate compliance with rigorous safety and quality standards. For companies like Swiss Parenterals, adhering to these regulations is crucial to maintain and expand their presence in EU markets.
Swiss Parenterals Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened scrutiny regarding quality and compliance. Indian exporters, including Swiss Parenterals, must navigate complex regulatory environments, ensuring adherence to FDA, WHO, and EU GMP standards. The US FDA's increased inspections of Indian facilities underscore the importance of maintaining high-quality manufacturing practices to avoid potential export bans or recalls. (fact.net.in)
Swiss Parenterals' integration into Eris Lifesciences is expected to bolster its compliance infrastructure, leveraging Eris's established quality management systems to meet international regulatory requirements effectively.
About Swiss Parenterals Limited
Swiss Parenterals Limited exports 18 products worth $15.9M. Beyond Meropenem, top products include Ceftriaxone, Prednisolone, Fosfomycin, Methylprednisolone, Hydrocortisone. View the complete Swiss Parenterals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Meropenem — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Meropenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Swiss Parenterals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 47 individual customs records matching Swiss Parenterals Limited exporting Meropenem, covering 37 formulations to 15 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 134+ countries, 966+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Meropenem Export Data from Swiss Parenterals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Swiss Parenterals Limited's Meropenem exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Swiss Parenterals Limited
Full Company Profile →
18 products · $15.9M total trade · 9 categories
Meropenem Stats
Company Overview
Top Products by Swiss Parenterals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Swiss Parenterals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Meropenem. For current shipment-level data, contact TransData Nexus.